Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Goldman Sachs Healthcare CEOs Unscripted Conference with William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Thursday, January 6, 2011 in New York.

 

What:

Teva Presentation at the Goldman Sachs Healthcare CEOs Unscripted Conference
 

Who:

William Marth, President & CEO, Teva Pharmaceuticals – Americas
 

When:

Thursday, January 6, 2011 at 12:00 p.m. ET
 

Where:

www.tevapharm.com/financial/ or

http://cc.talkpoint.com/gold006/010611a_mg/?entity=4_GHGQ6RI

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will also be available on Teva's website.
 

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Suggested Articles

Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.